MMV Pre-referral treatment, severe malaria, page-27

At this stage worrying about the number of shares on issue is neither here or there. The fact that the company needs to put a deal together with dollars attached to it is the most pressing issue at this point in time. Assuming the front line products of which there are seven do attract investors over the next 12 months; the cash that these deals will generate will allow suda to do a share consolidation, share buy back or issue dividends. Or maybe invest the money by bringing other products on line of which there are around three hundred to choose from. I believe once they can get the first deal done it should set the bench mark for other deals to happen. If they don't get the first deal right then it is going to be an uphill battle from there.

With the work that is happening behind the scenes including attending conferences, acquiring regulatory approval from various agencies, employing new staff to expand the front line production, getting the capital raising out of the way before reaching crisis point and having ongoing discussions with potential clients - it can only be a matter of time before we start seeing results.